鱼跃医疗(002223) - 2022 Q3 - 季度财报

Financial Performance - Q3 2022 revenue was CNY 1,563,475,489.70, a decrease of 8.97% year-over-year, while year-to-date revenue reached CNY 5,116,277,433.29, down 3.65% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was CNY 347,595,835.66, a decline of 10.61% year-over-year, with year-to-date net profit at CNY 1,135,461,466.82, down 15.99%[3] - Basic earnings per share for Q3 2022 was CNY 0.3469, reflecting an 11.73% decrease compared to the same period last year[3] - Total revenue for the third quarter was CNY 5,116,277,433.29, a decrease of 3.65% compared to CNY 5,310,255,530.07 in the same period last year[15] - The total operating profit for Q3 2022 was approximately CNY 1.28 billion, a decrease of 16.9% compared to CNY 1.54 billion in Q3 2021[16] - Net profit attributable to shareholders of the parent company was CNY 1.14 billion, down 16.0% from CNY 1.35 billion in the same period last year[17] - The company reported a total comprehensive income of CNY 1.11 billion, a decrease of 17.2% from CNY 1.35 billion in Q3 2021[17] - Basic and diluted earnings per share were both CNY 1.1332, down from CNY 1.3609 in Q3 2021[17] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period increased by 7.20% to CNY 1,166,050,200.60[3] - The company reported a net investment income of CNY 58,637,340.92, down from CNY 79,936,438.87 in the previous year[15] - Cash inflow from investment activities totaled CNY 6.52 billion, an increase of 17.4% compared to CNY 5.55 billion in Q3 2021[19] - The net cash flow from investment activities was negative at CNY -75.1 million, an improvement from CNY -1.50 billion in the same period last year[19] - Cash and cash equivalents at the end of the period reached CNY 3.45 billion, up 30.6% from CNY 2.64 billion at the end of Q3 2021[19] Assets and Liabilities - Total assets as of the end of the reporting period were CNY 13,215,428,898.56, representing a 10.15% increase from the end of the previous year[3] - Total liabilities amounted to CNY 3,912,192,317.29, compared to CNY 3,568,221,107.80, indicating an increase of 9.63%[14] - The company's equity attributable to shareholders rose to CNY 9,172,679,096.23 from CNY 8,272,114,352.19, a growth of 10.87%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 69,752, with the top ten shareholders holding significant stakes[8] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of shares, amounting to 245,983,450 shares, while Wu Guangming holds 10.32% with 103,438,537 shares[9] - The company has repurchased a total of 12,852,383 shares, representing 1.28% of the total share capital, with a total transaction amount of approximately 364.91 million RMB[10] - The first lock-up period for the employee stock ownership plan has expired, allowing for the release of 3,311,108 shares, which is 0.33% of the total share capital[11] - The top ten shareholders include various institutional investors, with the largest being Jiangsu Yuyue Technology Development Co., Ltd. and several mutual funds[9] - The company has a total of 6,622,216 shares allocated to the employee stock ownership plan, which were transferred at a price of 22.50 RMB per share[11] - The maximum and minimum repurchase prices during the buyback were 29.87 RMB and 27.60 RMB per share, respectively[10] - The total number of preferred shareholders is zero, indicating no preferred shares are currently held[8] Operational Costs and Expenses - Operating costs increased to CNY 4,047,920,990.46, up 4.26% from CNY 3,882,930,768.81 in the previous year[15] - Research and development expenses rose to CNY 381,392,719.03, reflecting a 22.25% increase from CNY 311,814,885.80 year-over-year[15] - The company experienced a 790.64% increase in fair value gains compared to the same period last year, attributed to increased interest income from structured deposits[7] - The company’s financial expenses decreased by 494.92% year-over-year, mainly due to exchange gains from currency fluctuations[6] Other Information - The company plans to continue expanding its market presence and invest in new product development[15] - The company did not conduct any audited financial report for Q3 2022[20] - The company experienced a foreign currency translation loss of CNY 3.57 million, compared to a loss of CNY 7.17 million in the previous year[17] - Accounts receivable increased by 60.21% compared to the beginning of the period, indicating a rise in reasonable receivables from normal business operations[6]